|Apply no later than||02 August 2020|
The general aims of the division of Experimental Hematology are to obtain detailed knowledge on (molecular) mechanisms that determine hematopoietic stem cell self-renewal and differentiation, with the ultimate goal to deepen our insights in the development of acute myeloid leukemia (AML). We perform gene-function analyses in primary human hematopoietic stem and progenitor cells utilizing various strategies including optimized lentiviral transduction protocols and inducible RNAi/CRISPR-Cas9 approaches. Furthermore, we use proteomics approaches for quantitative protein interactome analyses and ChIP-qPCR/seq approaches to investigate epigenetic regulation of gene expression in normal versus leukemic cells.
A four-year PhD/AIO position, funded by the Dutch Cancer Society (KWF), is available in the group of dr. V. van den Boom and prof.dr. J.J. Schuringa. Polycomb proteins are important epigenetic regulators that instruct cell fate decisions of normal hematopoietic stem cells and leukemic stem cells. We have previously shown that a specific non-canonical Polycomb complex, named PRC1.1, is essential for leukemic cell viability (Van den Boom et al. Cell Reports, 2016). Recently, we identified the deubiquitinase USP7 as an integral component of this complex. The aim of this study is to further dissect the exact molecular function of the PRC1.1 complex and USP7 in leukemic cells using state-of-the-art proteomics analyses, ChIP-seq/RNA-seq analysis in primary AML patient cells, and inducible knockout models. Furthermore, we will test the effectiveness of USP7 inhibitors in eradicating leukemic stem cells, both in vitro and in vivo using xenograft mouse models.
- Required education: MSs in biomedical/life-sciences related subject.
- Experience with cell biological techniques (i.e. eukaryotic tissue culture) is required.
- Experience with epigenetic techniques (i.e. ChIP) is a pro.
- Excellent writing and speaking/presentation skills in English.
- Ability to work independent.
- You are enthusiastic, ambitious and a team player.
The UMCG has a preventive Hepatitis B policy. The UMCG can provide you with the vaccination, should it be required for your position.
In case of specific professions a ‘Certificate of Good Conduct’ is required.
What do we need
The initial duration of the position is 1 year with the possibility of further extension for a full-time contract for maximum of 4 years. Extension of the contract will be based on sufficient progress and the expectation of a successful completion of the PhD project in the next three years.
Your salary will be a minimum of € 2.495,- gross per month in the first year and a maximum of € 3.196,- (scale PhD) in the final (4th) year, based on a full-time appointment. In addition, the UMCG will offer you 8% holiday pay, and 8.3% end-of-year bonus.
The conditions of employment comply with the Collective Labour Agreement for Medical Centres (CAO-UMC). English: http://www.nfu.nl/english/about-the-nfu/
What do we offer
For more information please contact:
- dr. V. van den Boom, phone: +31 50 361 1244, e-mail:
- prof. dr. J.J.Schuringa, phone: +31 50 361 9391, e-mail:
Please do not use the e-mail addresses for applications.
Applying for a job
Please use the the digital application form at the bottom of this page - only these will be processed. You can apply until 2 August 2020.
Within half an hour after sending the digital application form you will receive an email- confirmation with further information.